Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH? [2] (multiple letters)

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 6, 2004, Pages 924-

  Pitoia, Fabián ^a   Niepomniszcze, Hugo ^a   Degrossi, Osvaldo J ^b   Luster, Markus ^c  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b Instituto Argentino de Diagnostico y Tratamiento   (Argentina)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROXINE;

DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG POTENCY; DRUG SAFETY; HUMAN; LETTER; THYROID CARCINOMA; TREATMENT OUTCOME;

EID: 2942556656     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1502-4     Document Type: Letter

References (2)

1. 1. Luster 2003 Eur J Nucl Med Mol Imaging 30 1371 10.1007/s00259-003-1230-1 1:CAS:528:DC%2BD3sXnslSnt7g%3D 12856155 Luster M, Sherman SI, Skarulis MC et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003; 30:1371–1377.
2. 2. Pacini 2002 J Clin Endocrinol Metab 87 4063 Pacini F, Molinaro E, Castagna MG et al. Ablation of thyroid residues with 30 mCi 131 I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87:4063–4068.